Tesamorelin

Start with the condition, then the compound

Tesamorelin resembles growth hormone-releasing hormone, the brain’s signal asking the pituitary gland to release growth hormone. The resulting hormone response can also raise IGF-1, a growth-related signal in the body. Understanding the pathway does not establish that it is useful for every recovery goal.

The approved brand EGRIFTA is for reducing excess abdominal fat in adults with HIV who have lipodystrophy, a change in the way body fat is distributed. The approved prescribing information limits that indication and says the product is not for weight-loss management. This is orientation to an approved medicine, not a statement about the product supplied through any other service.

Human evidence belongs to the population studied

The large trial in adults with HIV compared tesamorelin with a placebo, a treatment without the active medicine. Researchers measured fat deep inside the abdomen, around the organs. The findings concern that medical context; they are not recovery research in otherwise healthy dancers, musicians or athletes.

A trial can be stronger than a collection of personal reports and still be the wrong trial for a different question. It does not establish that someone returns to rehearsal sooner, sleeps better or performs differently. Body-weight changes, deep abdominal fat and tissue recovery are separate measurements.

Research outside the approved indication does not widen the approval. A label’s existence also does not make an unapproved preparation equivalent to the studied product. Identity, formulation and the condition being treated remain central to interpreting what a paper means.

The warnings are part of the same evidence

The approved product’s label identifies fluid retention, joint discomfort, injection-site reactions, allergic reactions and changes in blood sugar. Fluid retention means the body holds extra water; it can contribute to swelling or pressure on nerves. IGF-1 can rise above the normal range, and the label describes uncertainty about the consequences of prolonged elevation.

The label rules out use in pregnancy, active cancer, certain pituitary problems and known allergy to the product. It also gives cautions about a past cancer and other medicines. These are facts about the approved product’s label, not a checklist that makes another preparation suitable for self-selection.

Approval and compounding are different questions

Tesamorelin’s FDA product record identifies it as a biologic, a legal category that matters for access. Ordinary pharmacy-compounding exemptions do not authorize copying a biologic. A different name on a product page does not remove that restriction.

Compounded tesamorelin is not FDA-approved. It is not interchangeable with the approved product simply because both use the word tesamorelin. This distinction deserves an explicit answer before any discussion moves from reading about the compound to a proposed prescription.

What to take into a provider conversation

Promise Peptides has a tesamorelin product listing and a licensed U.S. provider reviews each request. That is not a statement that Promise supplies the approved brand. Not everyone qualifies, and the service is for U.S. patients, with availability varying by state and treatment.

The provider needs to identify the exact product, its lawful basis and the medical reason it is being considered. The listing does not establish a lawful compounding route or show that the approved brand is being prescribed. Your history, including pituitary disease, blood-sugar problems, cancer and pregnancy, changes the clinical conversation.

The 2026 anti-doping list names tesamorelin as prohibited at all times. Permission under sport rules is separate from the existence of an approved medical use. For the wider recovery question, the five-way comparison helps show why this compound’s evidence belongs in a different column from rat tendon experiments and untested blends.